Therapy Areas: Diabetes
Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis
30 March 2026 - US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Saturday that Repatha (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering tr...
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
30 March 2026 - New Zealand-based soft tissue repair specialist Aroa Biosurgery Limited announced on Sunday completion of its randomised controlled trial (RCT) evaluating Symphony in patients with dia...
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
27 March 2026 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for Awiqli (in...
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
...
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
...
Andel launches new direct-to-employer medication platform for GLP-1s
12 March 2026 - Healthcare technology platform Andel Co-op Inc announced on Wednesday the launch of its app and medication platform in the United States, giving companies a new way to make GLP-1s an a...